{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:01:40Z","timestamp":1761742900170},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.ctrv.2006.10.004","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T12:21:59Z","timestamp":1166012519000},"page":"78-84","source":"Crossref","is-referenced-by-count":46,"title":["Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Luciano Jose","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2006.10.004_bib1","unstructured":"Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK, editors. SEER cancer statistics review; 1975\u20132003, National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2003\/, based on November 2005 SEER data submission, posted to the SEER web site 2006."},{"issue":"26","key":"10.1016\/j.ctrv.2006.10.004_bib2","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1073\/pnas.91.26.12574","article-title":"RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12\/rapamycin complex","volume":"91","author":"Chiu","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ctrv.2006.10.004_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0092-8674(02)00725-0","article-title":"Structure and function of the eukaryotic ribosome: the next frontier","volume":"109","author":"Doudna","year":"2002","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ctrv.2006.10.004_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0092-8674(02)00619-0","article-title":"Ribosome structure and the mechanism of translation","volume":"108","author":"Ramakrishnan","year":"2002","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ctrv.2006.10.004_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/bies.10362","article-title":"Starting the protein synthesis machine: eukaryotic translation initiation","volume":"25","author":"Preiss","year":"2003","journal-title":"Bioessays"},{"issue":"7025","key":"10.1016\/j.ctrv.2006.10.004_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature03205","article-title":"Regulation of cap-dependent translation by eIF4E inhibitory proteins","volume":"433","author":"Richter","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ctrv.2006.10.004_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/geno.1996.0638","article-title":"Tissue distribution, genomic structure, and chromosome mapping of mouse and human eukaryotic initiation factor 4E-binding proteins 1 and 2","volume":"38","author":"Tsukiyama-Kohara","year":"1996","journal-title":"Genomics"},{"issue":"15","key":"10.1016\/j.ctrv.2006.10.004_bib8","doi-asserted-by":"crossref","first-page":"10240","DOI":"10.1074\/jbc.272.15.10240","article-title":"Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes","volume":"272","author":"Fadden","year":"1997","journal-title":"J Biol Chem"},{"issue":"Pt 1","key":"10.1016\/j.ctrv.2006.10.004_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1042\/bj3360039","article-title":"Insulin-stimulated kinase from rat fat cells that phosphorylates initiation factor 4E-binding protein 1 on the rapamycin-insensitive site (serine-111)","volume":"336","author":"Heesom","year":"1998","journal-title":"Biochem J"},{"issue":"10","key":"10.1016\/j.ctrv.2006.10.004_bib10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0960-9822(03)00329-4","article-title":"TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function","volume":"13","author":"Schalm","year":"2003","journal-title":"Curr Biol"},{"issue":"18","key":"10.1016\/j.ctrv.2006.10.004_bib11","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.ctrv.2006.10.004_bib12","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"issue":"6","key":"10.1016\/j.ctrv.2006.10.004_bib13","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/ncb996","article-title":"Rheb promotes cell growth as a component of the insulin\/TOR signalling network","volume":"5","author":"Saucedo","year":"2003","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.ctrv.2006.10.004_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ncb995","article-title":"Rheb is an essential regulator of S6K in controlling cell growth in Drosophila","volume":"5","author":"Stocker","year":"2003","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.004_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"issue":"38","key":"10.1016\/j.ctrv.2006.10.004_bib16","doi-asserted-by":"crossref","first-page":"35364","DOI":"10.1074\/jbc.M205838200","article-title":"Phosphatidylinositol 3-kinase\/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin","volume":"277","author":"Dan","year":"2002","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.ctrv.2006.10.004_bib17","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin","volume":"22","author":"Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.ctrv.2006.10.004_bib18","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1074\/jbc.M309999200","article-title":"AKT activity determines sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression","volume":"279","author":"Gera","year":"2004","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.ctrv.2006.10.004_bib19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"issue":"18","key":"10.1016\/j.ctrv.2006.10.004_bib20","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ctrv.2006.10.004_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2004.05.024","article-title":"Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells","volume":"5","author":"Avdulov","year":"2004","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ctrv.2006.10.004_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccr.2004.05.027","article-title":"Lost in translation: dysregulation of cap-dependent translation and cancer","volume":"5","author":"Bjornsti","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2006.10.004_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1357-2725(98)00132-0","article-title":"eIF4E expression in tumors: its possible role in progression of malignancies","volume":"31","author":"De Benedetti","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2006.10.004_bib24","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1128\/MCB.12.3.1234","article-title":"The mRNA 5\u2032 cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts","volume":"12","author":"Lazaris-Karatzas","year":"1992","journal-title":"Mol Cell Biol"},{"issue":"6980","key":"10.1016\/j.ctrv.2006.10.004_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.004_bib26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nm1042","article-title":"The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis","volume":"10","author":"Ruggero","year":"2004","journal-title":"Nat Med"},{"issue":"20","key":"10.1016\/j.ctrv.2006.10.004_bib27","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/jnci\/93.20.1517","article-title":"Rapamycin\u2019s resurrection: a new way to target the cancer cell cycle","volume":"93","author":"Garber","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"56","key":"10.1016\/j.ctrv.2006.10.004_bib28","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","article-title":"The rapamycin-sensitive signal transduction pathway as a target for cancer therapy","volume":"19","author":"Hidalgo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2006.10.004_bib29","unstructured":"Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood, in press."},{"issue":"13","key":"10.1016\/j.ctrv.2006.10.004_bib30","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/0008-5472.CAN-05-3018","article-title":"Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"66","author":"Vega","year":"2006","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2006.10.004_bib31","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood.V96.13.4319","article-title":"Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase\/Akt antiapoptotic signaling pathway","volume":"96","author":"Bai","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.004_bib32","first-page":"2194","article-title":"Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagenesis","volume":"61","author":"lupianek","year":"2001","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2006.10.004_bib33","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2006.10.004_bib34","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2004-11-4468","article-title":"mTOR regulates cell survival after etoposide treatment in primary AML cells","volume":"106","author":"Xu","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2006.10.004_bib35","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","article-title":"The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL","volume":"107","author":"Teachey","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.004_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","article-title":"Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab","volume":"134","author":"Wanner","year":"2006","journal-title":"Br J Haematol"},{"issue":"5712","key":"10.1016\/j.ctrv.2006.10.004_bib37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor\u2013mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ctrv.2006.10.004_bib38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2006.10.004_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov dos","year":"2006","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.ctrv.2006.10.004_bib40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1440-1797.2005.00493.x","article-title":"Sirolimus: its role in nephrology","volume":"10","author":"Lee","year":"2005","journal-title":"Nephrology (Carlton)"},{"issue":"23","key":"10.1016\/j.ctrv.2006.10.004_bib41","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2006.10.004_bib42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa051175","article-title":"Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization","volume":"353","author":"Windecker","year":"2005","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ctrv.2006.10.004_bib43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2006.10.004_bib44","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2006.10.004_bib45","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.004_bib46","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"issue":"S","key":"10.1016\/j.ctrv.2006.10.004_bib47","article-title":"A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)","volume":"24","author":"Hudes","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.004_bib48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.21265","article-title":"CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium","volume":"104","author":"Margolin","year":"2005","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2006.10.004_bib49","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.004_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00001813-200606000-00001","article-title":"Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway","volume":"17","author":"Smolewski","year":"2006","journal-title":"Anticancer Drugs"},{"issue":"S","key":"10.1016\/j.ctrv.2006.10.004_bib51","article-title":"Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas","volume":"24","author":"Chawla","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2006.10.004_bib52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","article-title":"Everolimus: a review of its use in renal and cardiac transplantation","volume":"66","author":"Dunn","year":"2006","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.ctrv.2006.10.004_bib53","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2006.10.004_bib54","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206002052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206002052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T07:46:42Z","timestamp":1587282402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737206002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0305737206002052"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2006.10.004","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}